Innocutis recently introduced Sitavig ®(ACYCLOVIR) 50mg Buccal Tablet to North American markets for the treatment of herpes labialis. Sitavig uses a proprietary delivery technology which consists of a tasteless and odorless tablet that sticks to the gum above the incisor tooth on the side of the lip that is infected with a cold sore. It then dissolves to provide a sustained release of medicine. A Phase III, randomized, double-blind, placebo controlled study demonstrated that a single low dose of Sitavig acyclovir buccal tablet improved all clinical parameters of labial herpes when applied shortly after symptoms occurred, according to the company. It also decreased duration of episode, increased the percentages of blocked lesions, and delayed by 105 days the recurrence of the next herpes episodes.